A few days ago, Pfizer CEO Aberle said that the surge in demand for Paxlovid in the Chinese market has led to tight supply, and it is working with a Chinese contract drugmaker to prepare for local production
.
It is understood that last year, Huahai Pharmaceutical won the Pfizer Paxlovid preparation commission production agreement - Huahai Pharmaceutical will provide preparation commission production services for Pfizer's new coronavirus treatment Paxlovid sold in the Chinese mainland market during the agreement period (5 years) to meet the drug needs
of Chinese patients.
Not long ago, Huahai Pharmaceutical said in response to investors that "the company is actively cooperating with Pfizer to accelerate the localization of Paxlovid to ensure the sufficient supply of Paxlovid in the Chinese market and continue to meet the treatment needs of
Chinese patients.
" ”
In recent years, with the continuous growth of the overall domestic pharmaceutical market, the Chinese market has become the engine
of growth for foreign-funded pharmaceutical companies.
At the same time, in the face of China's huge pharmaceutical market, "localization" has gradually become the keyword
of multinational pharmaceutical companies.
At present, a large number of multinational pharmaceutical companies are not only innovating cooperation models with domestic parties to empower China's biopharmaceutical industry, but also working together to build a broader local pharmaceutical R&D ecosystem in China
.
In addition to Pfizer, as early as October 11, 2021, AstraZeneca's Global R&D China Center has been fully upgraded and officially opened in Shanghai Jing'an District, becoming an important milestone
in AstraZeneca's R&D strategic layout in China.
It is expected that by 2023, AstraZeneca's R&D investment in China will be 2.
5 times that of 2020; the number of R&D personnel in China is planned to increase to more than 800, and the personnel growth rate will reach 60%
compared with 2020.
Also on April 20, 2021, Sartorius announced the official opening of its new Customer Engagement Center (CIC) in Beijing's Shunyi District to serve its expanding business
in China.
The opening of the Customer Interaction Center marks the completion of the first phase of the expansion of Sartorius' existing production facility in Beijing, with an additional 670 square meters now available for demonstrations and factory acceptance testing (FAT).
In addition, Novartis and Zhangjiang Group have already signed a memorandum of cooperation on
Novartis China Life Sciences Open Innovation Platform.
In the future, Novartis will work with Zhangjiang Group to incubate and accelerate innovative projects in healthcare, life sciences and other fields, and promote the construction
of China's biomedical ecosystem.
It is expected that by the end of 2024, Novartis will submit more than 50 new drug applications in China, and aims to achieve more than 90% of new drug registrations in China in sync with the world by 2024
.
.
.
.
.
.
.
With the continuous reform of pharmaceutical policies, the rise of local pharmaceutical innovation forces, coupled with the acceleration of demographic dividend and aging trend, China's pharmaceutical market has become a must for overseas pharmaceutical companies
.
The industry expects that in the future, multinational pharmaceutical companies will continue to follow the reform and development trend of China's medical industry and accelerate their innovation strategies, in order to better integrate into the Chinese market and gain more market growth space
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
